{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigoxrz5ledbpfvp2fwdmv3dyajlv2m4kmdyxhx76isnl23dyqxs7u",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm4zfqzwv2c2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicem25vp2vdaa5nrplp4cgwjt5vgn35wn2ahwijy6ua6jcc2ym5uy"
    },
    "mimeType": "image/jpeg",
    "size": 582400
  },
  "path": "/news/2026-05-polyendocrine-metabolic-syndrome-doesnt-menopause.html",
  "publishedAt": "2026-05-18T09:40:07.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Polycystic Ovary Syndrome, which has just been renamed Polyendocrine Ovarian Syndrome (PMOS), is the most common hormonal and metabolic disorder affecting women of reproductive age, impacting up to 13% of this population and contributing to nearly 40% of infertility cases worldwide. The condition is marked by a complex combination of hormonal imbalance, insulin resistance, metabolic dysfunction and inflammation, often leading to irregular menstrual cycles, weight gain and increased cardiovascular and diabetes risk.",
  "title": "Polyendocrine metabolic syndrome doesn't end at menopause and neither should its care, research shows"
}